The global carrier screening market is expected to experience significant growth, with a projected compound annual growth rate (CAGR) of 12.4% from 2023 to 2033. Estimated at USD 1,343.40 million in 2023, the market is anticipated to reach USD 4,323.84 million by 2033, driven by increasing demand for genetic testing, advancements in diagnostic technologies, and expanding funding from both public and private sectors.
Rising Demand for Genetic Testing Fuels Market Expansion:
The growing prevalence of genetic defects and chronic diseases has heightened the demand for carrier screening, making genetic testing a crucial tool for early diagnosis and prevention. Increased investments in healthcare and diagnostics are further propelling market growth, particularly with the introduction of innovative tests designed to enhance diagnosis and treatment.
As technology becomes more accessible, the adoption of carrier screening tests is expected to accelerate, providing better outcomes for individuals and families at risk for inherited genetic disorders.
Strategic Mergers, Acquisitions, and Innovations Drive Market Dynamics:
Industry players are strengthening their positions through strategic mergers, agreements, and acquisitions. In a notable move, Counsyl, Inc. expanded its partnership with Angsana Molecular & Diagnostics Laboratory in 2017 to sell the Extended Carrier Screening (ECS) test in Hong Kong. Subsequently, Myriad Genetics, Inc. acquired Counsyl in 2018, enhancing its portfolio of genetic tests.
Furthermore, the launch and approval of new carrier screening tests are expected to play a key role in fueling market expansion in the coming years.
Regional Insights: North America Leads, Europe Follows Suit
North America is set to maintain its dominance in the carrier screening market, driven by the approval of new products and the introduction of innovative genetic tests. A prime example is Sema4’s announcement in October 2019 of the availability of the Expanded Carrier Screen, a test that helps estimate the likelihood of a child inheriting a genetic condition.
Europe is also seeing strong growth, with the launch of cutting-edge screening tests such as QIAGEN’s QIAseq Expanded Carrier Screening Panel in June 2019. This test, which offers insight into genes associated with 200 disease indications, marks a significant milestone in molecular diagnostics.
The continued development of novel tests and increased adoption of carrier screening technologies are expected to sustain the market’s upward trajectory, benefiting both healthcare providers and patients worldwide.
Key Takeaways:
- With a 12.9% CAGR between 2023 and 2033, the expanded carrier screening (ECS) segment is anticipated to be the key revenue-generating market.
- Through 2033, the DNA sequencing market sector held a 39.9% revenue share, dominating the carrier screening market.
- With a 47.1% carrier screening market share throughout the projection period, the laboratory segment dominated the global market.
- With a share of 40.19% through 2033, the North American market is anticipated to hold a leading position in the carrier screening market.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Competitive Landscape:
There are several significant participants in the fragmented and competitive carrier screening market. A small number of significant businesses control a large portion of the market.
The market’s overall competitive rivalry is growing as a result of the existence of significant players including Abbott, F. Hoffmann-La Roche AG, Danaher Corporation (Cepheid), Illumina Inc., and Thermo Fisher Scientific Inc.
Recent Development:
Collaboration – To Co-develop:
Illumina and Kartos Therapeutics, Inc. announced a collaboration to co-develop a TP53 companion diagnostic (CDx) in April 2021. This CDx is based on the information provided by Illumina’s comprehensive genomic profile assay, TruSight Oncology.
Partnership – Utilizing the Skills of Both Parties:
Fulgent and Precision Genomics Laboratory (PGL) partnered in January 2019 to offer Columbia patients on-site performed, expanded carrier screening.
Acquisition – For Expansion:
Fulgent purchased CSI Laboratories (CSI) in August 2021 to increase its exposure to somatic molecular diagnostics and cancer testing. CSI provides molecular genetics, immunohistochemistry, fluorescence in-situ hybridization (FISH), and cytogenetic studies.
Key Players:
- Myriad Genetics, Inc
- Cepheid
- Illumina
- Thermo Fisher Scientific Inc.
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Otogenetics
- MedGenome
- GeneTech
- Centogene N.V.
Key Segments:
By Type:
- Expanded Carrier Screening
- Targeted Disease Carrier Screening
By Medical Condition:
- Cystic Fibrosis
- Tay-Sachs
- Gaucher Disease
- Sickle Cell Disease
- Spinal Muscular Atrophy
- Other
By Technology:
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Other
By End User:
- Hospitals
- Laboratories
- Physician Offices & Clinics
- Other
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube